Anaemia of chronic kidney disease: what we know now.

Anoushka Krishnan, Deborah Trinder, Anita Chai-Geik Chua, Aron Chakera, Grant Ramm, John Olynyk

Research output: Contribution to journalReview articlepeer-review

364 Downloads (Pure)


Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably in
the last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of a
chronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factors
and signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agents
that could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators of
hepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapies
that could be available in the near future targeting the various factors that regulate hepcidin.
Original languageEnglish
Pages (from-to)11-19
Number of pages9
JournalJournal of Renal and Hepatic Disorders
Issue number1
Publication statusPublished - 3 Feb 2017


Dive into the research topics of 'Anaemia of chronic kidney disease: what we know now.'. Together they form a unique fingerprint.

Cite this